

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**GENZYME CORP**

2. Address:

1850 K Street, NW Suite 650, Washington, DC 20006

3. Principal place of business (if different from line 2):

City: Cambridge State/Zip(or Country): MA 02142

4. Contact Name: MARY MCGRANE

Telephone: 2022963280

E-mail (optional): mary.mcgrane@genzyme.com

Senate ID #: 16054-12

House ID #:

7. Client Name:  Self

## TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  OR Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 OR Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 1,280,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: GENZYME CORP Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

e) Patent reform issues. f) H.R. 1908 "Patent Reform Act of 2007" g) S.1145, "Patent Reform Act of 2007" a) Patent framework affecting generic biologics. b) S.1695, "Biologics Price Competition and Innovation Act of 2007" c) S.623, "Access to Life-Saving Medicine Act" d) H.R. 1038, Access to Life-Saving Medicine Act"

17. House(s) of Congress and Federal agencies contacted:

Executive Office of the President (EOP)

HOUSE OF REPRESENTATIVES

Patent & Trademark Office (PTO)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH

Covered Official Position (if applicable): N/A

Name: HOLCOMBE, KAY

Covered Official Position (if applicable): N/A

Name: MCGRANE, MARY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: GENZYME CORP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

e) S.1082 "FDA Revitalization Act of 2007" Provision Re: IOM Lab Study f) S.736, "The Laboratory Test Improvement Act" a) Reimbursement for clinical lab services under Medicare. b) H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act" c) S.976 "Genomics & Personalized Medicine Act of 2007" d) Competitive bidding for lab tests

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH

Covered Official Position (if applicable): N/A

Name: HOLCOMBE, KAY

Covered Official Position (if applicable): N/A

Name: MCGRANE, MARY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: GENZYME CORP Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

d) S.691/H.R. 1193 The Kidney Care Quality and Education Act e) H.R. 3162, The Children's Health and Medicare Protection Act of 2007 f) CPT Coding decisions g) Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician offices. h) Implementation of the Competitive Acquisition (CAP) Program for Part B Drugs. i) 340B Programs. j) CMS guidance on coverage under evidence development. k) Physicians fee schedule payment rates for lab tests. l) Medicaid budget reductions. m) Medicaid rebates n) H.R. 2184, the Enhanced Health Care Value for All Act o) Technology assessment report on osteoarthritis treatments a) Medicare Prescription Drug Benefit: Implementation of issues associated w/P.L. 108-173, including reimbursement for orphan drugs. b) H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act of 2007", reimbursement for lab tests c) Bundling Payment system for dialysis centers

17. House(s) of Congress and Federal agencies contacted:

Agency for Health Care Policy & Research  
Centers For Medicare and Medicaid Services (CMS)  
Executive Office of the President (EOP)  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH  
Covered Official Position (if applicable): N/A  
Name: HOLCOMBE, KAY  
Covered Official Position (if applicable): N/A  
Name: MCGRANE, MARY  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: GENZYME CORP Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

e) Senate Concurrent Resolution 21 f) S. 251, "Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. g) S. 242, "Pharmaceutical Market Access & Drug Safety Act of 2007" a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S. 1082, "Food & Drug Administration Revitalization Act of 2007" c) H.R. 2900, "Food & Drug Administration Amendments Act of 2007" d) H.R. 380, "Pharmaceutical Market Access and Drug Safety Act of 2007" - Importation.

17. House(s) of Congress and Federal agencies contacted:

Executive Office of the President (EOP)  
Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: FROELICH, SARAH  
Covered Official Position (if applicable): N/A  
Name: HOLCOMBE, KAY  
Covered Official Position (if applicable): N/A  
Name: MCGRANE, MARY  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: MARY MCGRANE, SENIOR VICE PRESIDENT, GOVERNMENT RE -

Registrant Name: GENZYME CORP Client Name: Self

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Aug 10, 2007

Printed Name and Title: -